Angina Pectoris

Angina Pectoris
Ansam Sharef, Ahmad Aswad
angina-pectoris.ppt

Drugs for Angina Pectoris and Myocardial infarction
Drugs for Angina Pectoris and Myocardial infarction.ppt

Nitrovasodilators & Angina
Frank F. Vincenzi
Nitrovasodilators & Angina.ppt

Antithrombotic Treatment and the Incidence of Angina Pectoris
Gloria Wu, M.D.
Antithrombotic Treatment and the Incidence of Angina Pectoris.ppt

Coronary Artery Disease-Cardiac Pharmacology
Myocardial Infarction
Cardiac Pharmacology.ppt

Drugs for Angina Pectoris
Drugs for Angina Pectoris.ppt

Chest Pain
James Nixon, MD
Chest Pain.ppt

Cardiovascular and Stroke Emergencies
Cardiovascular and Stroke Emergencies.ppt

Medpharm Drugs for Ischemic Heart Disease
Palmer-IschemicPresentation.ppt

NSTEMI
nstemi.ppt

Cardiovascular Pharmacology
Cardiovascular Pharmacology.ppt

Angina Pain and Related Cardiovascular Problems
Ric and Jennifer
Angina Pain.ppt

Ischemic Heart Disease
Adriana Acurio, M.D.
Ischemic Heart Disease.ppt

Angina Pectoris and Calcium Channel Blockers
Frank F. Vincenzi
Angina Pectoris and Calcium Channel Blockers.ppt

CVD and riskfactors
CVD and riskfactors.ppt

Diseases of the Heart
Diseases of the Heart.ppt

Introduction to Emergency Medical Care
Introduction to Emergency Medical Care.ppt

Myocardial Ischemia Manifests in Different Forms
Myocardial Ischemia.ppt

Drugs Affecting Cardiac and Renal Systems
Jan Bazner-Chandler
Drugs Affecting Cardiac and Renal Systems.ppt

Cardiovascular Drugs - Functional Components of the Heart
Cardiovascular.ppt

Published articles

1. Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention.
2. Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab: design and rationale of the High Intensity Transient Signals ReoPro (HITS-RP) study.
3. Segmental diastolic compression of circumflex coronary artery secondary to pericardial constriction: an uncommon cause of angina pectoris.
4. Sulfotanshinone sodium injection for unstable angina pectoris: a systematic review of randomized controlled trials.
5. Spinal cord stimulation for refractory angina pectoris -a case report-.
6. Meta-Analysis of Randomized Controlled Trials on the Efficacy of Di'ao Xinxuekang Capsule and Isosorbide Dinitrate in Treating Angina Pectoris.
7. Elevated serum adipocyte fatty acid-binding protein concentrations are independently associated with renal dysfunction in patients with stable angina pectoris.
8. Angina pectoris in patients with HIV/AIDS: prevalence and risk factors.
9. Relevance of I-BMIPP delayed scintigraphic imaging for patients with angina pectoris - a pilot study.
10. Systematic review and meta-analysis of randomized controlled trials comparing Chinese patent medicines Compound Danshen Dripping Pills and Di'ao Xinxuekang in treating angina pectoris.
11. Percutaneous coronary intervention with optimal medical therapy vs. optimal medical therapy alone for patients with stable angina pectoris.
12. Symptoms of anxiety and depression are correlates of angina pectoris by recent history and an ischemia-positive treadmill test in patients with documented coronary artery disease in the pimi study.
13. A comparative study of dalteparin and unfractionated heparin in patients with unstable angina pectoris.
14. Variant angina pectoris associated with FOLFOX4 therapy.
15. Effects of different statins, ezetimibe/simvastatin combination on hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial.
16. Recurrent variant angina pectoris due to Behçet's syndrome.
17. A case of pseudo-angina pectoris from a pectoralis minor trigger point caused by cross-country skiing.
18. Value and level of plasma homocysteine in patients with angina pectoris undergoing coronary angiographic study.
19. Development of cervical subarachnoid hematoma following coronal artery stenting for angina pectoris.
20. Management of refractory angina pectoris.
21. Correlation between serum growth differentiation factor-15 and TIMI risk scores in patients with unstable angina pectoris.
22. The diagnostic value of computed tomographic coronary angiography in patients with acute myocardial infarction versus stable angina pectoris: a preliminary report.
23. Changes of dendritic cells and fractalkine in type 2 diabetic patients with unstable angina pectoris: a preliminary report.
24. Serum creatinine is independently associated with angiographic extent of coronary artery disease in patients with stable angina pectoris.
25. A case of a senile systemic amyloidosis patient presenting with angina pectoris and dilated cardiomyopathy.
26. Increased levels of leukocyte-derived MMP-9 in patients with stable angina pectoris.
27. Spinal cord stimulation for the treatment of refractory angina pectoris.
28. The coronary sinus reducer stent for the treatment of chronic refractory angina pectoris.
29. Coronary sinus intervention for the treatment of refractory angina pectoris.
30. Long-term cardiovascular outcomes in patients with angina pectoris presenting with bundle branch block.
31. Smoking, alcohol consumption, physical activity, and family history and the risks of acute myocardial infarction and unstable angina pectoris: a prospective cohort study.
32. Effects of enhanced external counterpulsation on arterial stiffness and myocardial oxygen demand in patients with chronic angina pectoris.
33. Lipoprotein(a) Is the Best Single Marker in Assessing Unstable Angina Pectoris.
34. Vasospastic angina pectoris in the left main trunk detected by 64-slice multidetector computed tomography.
35. Gender differences of plaque characteristics in elderly patients with stable angina pectoris: an intravascular ultrasonic radiofrequency data analysis.
36. Coronary-cameral fistula with angina pectoris.
37. Anomalous origin of all three coronary arteries from right sinus of Valsalva in a patient with angina pectoris.
38. Comparison of tissue characteristics between acute coronary syndrome and stable angina pectoris. An integrated backscatter intravascular ultrasound analysis of culprit and non-culprit lesions.
39. Chest pain and angina pectoris - or the ugly swan and the beautiful duckling.
40. Atypical exercise stress myocardial perfusion SPECT imaging in a patient with effort angina pectoris.
41. Systematic review on the short-term efficacy and safety of nicorandil for stable angina pectoris in comparison with those of β-blockers, nitrates and calcium antagonists.
42. Is allopurinol a potential new treatment for angina pectoris?
43. C-reactive protein in unstable angina pectoris and its relation to coronary angiographic severity and diffusion scores of coronary lesions.
44. Depressive symptoms and all-cause mortality in unstable angina pectoris (from the Coronary Psychosocial Evaluation Studies COPES).
45. Thrombus aspiration in a series of patients with stable or unstable angina pectoris and lesion-site thrombus formation.
46. Stable angina pectoris: what does the current clinical evidence tell us?
47. Myocardial perfusion SPECT and dobutamine stress tissue Doppler imaging in evaluation of patients with stable angina pectoris.
48. The association of angina pectoris with heart disease mortality among men and women by diabetes status: the Rancho Bernardo Study.
49. Circulating CD34+/133+ progenitor cells in patients with stable angina pectoris undergoing percutaneous coronary intervention.
50. Target lesion thin-cap fibroatheroma defined by virtual histology intravascular ultrasound affects microvascular injury during percutaneous coronary intervention in patients with angina pectoris.
51. Evaluation of leptin and adiponectin levels in patients with stable angina pectoris.
52. Effect of prodromal angina pectoris on the infarct progression in patients with first ST-elevation acute myocardial infarction.
53. Prevalence of angina pectoris in Pelotas, south of Brazil.
54. Relationship between coronary artery remodeling and cumulative incidence of coronary angiographic lesions with vulnerable characteristics in patients with stable angina pectoris.
55. Anomalous single coronary artery presenting as typical angina pectoris: a case report.
56. Ischemia-modified albumin in differential diagnosis of acute coronary syndrome without ST elevation and unstable angina pectoris.
57. Troponin release following exercise test in patients with stable angina pectoris - risk factors and prognostic significance.
58. Is there a Failure to Optimize theRapy in anGina pEcToris (FORGET) study?
59. Coexistence of atherosclerosis and fistula as a cause of angina pectoris: a case report.
60. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial.
61. Double-blind and placebo-controlled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris.
62. A young woman with angina pectoris: a brief report.
63. Multiple coronary-cameral fistulae causing angina pectoris.
64. Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris.
65. Plaque location in the left anterior descending coronary artery and tissue characteristics in angina pectoris: an integrated backscatter intravascular ultrasound study.
66. Percutaneous coronary revascularization in patients with formerly "refractory angina pectoris in end-stage coronary artery disease" - not "end-stage" after all.
67. Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men.
68. Association of MCP-1 -2518 A/G single nucleotide polymorphism with the serum level of CRP in Slovak patients with ischemic heart disease, angina pectoris, and hypertension.
69. Recommendations for advancing the care of Canadians living with refractory angina pectoris: a Canadian Cardiovascular Society position statement.
70. Expression levels of Toll-like receptor genes in coronary atherosclerotic lesions of patients with acute coronary syndrome or stable angina pectoris.
71. Prognostic value of myocardial perfusion scintigraphy in type 2 diabetic patients with mild, stable angina pectoris.
72. Clinical effects of calcium channel blocker and Angiotensin converting enzyme inhibitor on endothelial function and arterial stiffness in patients with angina pectoris.
73. Appropriateness of diagnosis of unstable angina pectoris in patients referred for coronary arteriography.
74. Myocardial infarction patients show altered lipoprotein properties and functions when compared with stable angina pectoris patients.
75. Congenital coronary artery fistula as a cause of angina pectoris.
76. Glucose intolerance, insulin resistance and metabolic syndrome in patients with stable angina pectoris. Obesity predicts coronary atherosclerosis and dysglycemia.
77. A new combination therapy in stable angina pectoris.
78. Exercise-induced T wave normalization in a patient with stable angina pectoris.
79. Enhanced external counter pulsation in treatment of refractory angina pectoris: two year outcome and baseline factors associated with treatment failure.
80. A new method to quantify coronary calcification by intravascular ultrasound - the different patterns of calcification of acute myocardial infarction, unstable angina pectoris and stable angina pectoris.
81. Progression of non-culprit coronary artery atherosclerosis after acute myocardial infarction in comparison with stable angina pectoris.
82. Plasma levels of oxidized low density lipoprotein are associated with stable angina pectoris and modalities of acute coronary syndrome.
83. Presentation of stable angina pectoris among women and South Asian people.
84. Calcification of the thoracic aorta as detected by spiral computed tomography among stable angina pectoris patients: association with cardiovascular events and death.
85. Frequency and predictor of coronary thin-cap fibroatheroma in patients with acute myocardial infarction and stable angina pectoris a 3-vessel optical coherence tomography study.
86. Outcome of patients with stable angina pectoris treated with or without percutaneous coronary intervention.
87. Laws of syndrome element combination in stable angina pectoris: a study based on cluster analysis and corresponding-correlation analysis.
88. Clinical and cost-effectiveness analysis of an open label, single-centre, randomised trial of spinal cord stimulation (SCS) versus percutaneous myocardial laser revascularisation (PMR) in patients with refractory angina pectoris: The SPiRiT trial.
89. Myocardial infarction and angina pectoris in the history of Polish medicine. Part 2. Diagnosis and early attempts at treatment: the 19th and 20th centuries.
90. Myocardial infarction and angina pectoris in the history of Polish medicine. Part 1. Discovery and understanding of the disease.
91. Case images: multiple fistulae between the left coronary arteries and left ventricle in a patient with angina pectoris.
92. Bilateral coronary artery-pulmonary artery fistulas in a case with unstable angina pectoris.
93. An unusual case of angina pectoris: a patient with isolated non-compaction of the left ventricular myocardium.
94. Angina pectoris and the Arnolds: emotions and heart disease in the nineteenth century.
95. Inequity of access to investigation and effect on clinical outcomes: prognostic study of coronary angiography for suspected stable angina pectoris.
96. Acute coronary syndrome in the form of variant angina pectoris while performing stress echocardiography.
97. Non-compaction cardiomyopathy presenting with classical angina pectoris.
98. Angina pectoris: reversal of the gender gap.
99. Direct stenting for stable angina pectoris is associated with reduced periprocedural microcirculatory injury compared with stenting after pre-dilation.
100. Effect of mean platelet volume on postintervention coronary blood flow in patients with chronic stable angina pectoris.
101. Relationship between resistin level in serum and acute coronary syndrome or stable angina pectoris.
102. Effect of enhanced external counterpulsation on inflammatory cytokines and adhesion molecules in patients with angina pectoris and angiographic coronary artery disease.
103. Angina pectoris in a young athlete with anomalous coronary artery.
104. Belching as a presenting symptom of angina pectoris.
105. Extraction, combination and distribution regularity of syndrome elements in patients with variant angina pectoris.
106. Serum deoxyribonuclease I activity can be used as a novel marker of transient myocardial ischaemia: results in vasospastic angina pectoris induced by provocation test.
107. Intensity of C-reactive protein immunohistochemical staining of atherosclerotic plaque macrophages and extracellular tissue of patients with angina pectoris undergoing directional coronary atherectomy.
108. Optimal medical therapy in stable angina pectoris--CURAGE clinical trail.
109. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms.
110. Single coronary artery as cause of non-atheromatous angina pectoris: multidetector computed tomography assessment.
111. Successful treatment of refractory angina pectoris due to multivessel coronary spasm with valsartan.
112. Gender differences in the clinical management of patients with angina pectoris: a cross-sectional survey in primary care.
113. Endoscopic thoracic sympathectomy--its effect in the treatment of refractory angina pectoris.
114. Multicentric randomized double blinded clinical study of Yiqi Tongmai Oral Liquid against angina pectoris in patients with coronary heart disease.
115. Angina pectoris: has the cornerstone of symptomatic coronary artery disease been moved?
116. High probability of disease in angina pectoris patients: is clinical estimation reliable?
117. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial.
118. Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China.
119. Coronary and aortic calcifications inter-relationship in stable angina pectoris: A Coronary Disease Trial Investigating Outcome with Nifedipine GITS (ACTION)--Israeli spiral computed tomography substudy.
120. Genetic influences on angina pectoris and its impact on coronary heart disease.
121. Angina pectoris in patient with hyperthyroidism and normal angiography coronary.
122. Epidemiology of angina pectoris: role of natural language processing of the medical record.
123. Adjunctive value of CT coronary angiography in the diagnostic work-up of patients with typical angina pectoris.
124. Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study.
125. Multiple rare causes of typical angina pectoris in a single patient.
126. Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure.
127. High technology and placebo effect: myocardial laser revascularization in the palliative treatment of refractory angina pectoris.
128. Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris undergoing elective percutaneous coronary interventions.
129. Thoracic spinal cord stimulation improves functional status and relieves symptoms in patients with refractory angina pectoris: the first placebo-controlled randomised study.
130. Angina pectoris and intensive intravenous iron treatment in hemodialysis patients.
131. Guidelines on the management of stable angina pectoris. Executive summary.
132. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study.
133. Efficacy and safety of controlled-release isosorbide-5-mononitrate in Japanese patients with stable effort angina pectoris.
134. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris.
135. Successive, rapid recurrences of in-stent restenoses in a woman with angina pectoris.
136. Spinal cord stimulation for refractory angina pectoris and peripheral vascular disease.
137. Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology.
138. Guidelines on the management of stable angina pectoris.
139. Guidelines on the management of stable angina pectoris; the experts of the European Society of Cardiology on the management of stable angina pectoris.
140. Prognosis of stable angina pectoris: why we need larger population studies with higher endpoint resolution.
141. An aneurysm of the distal portion of the left anterior descending coronary artery associated with angina pectoris.
142. Images in cardiovascular medicine. Hybrid cardiac single photon emission computed tomography/computed tomography imaging with myocardial perfusion single photon emission computed tomography and multidetector computed tomography coronary angiography for the assessment of unstable angina pectoris after coronary artery bypass grafting.
143. One year follow-up of patients with refractory angina pectoris treated with enhanced external counterpulsation.
144. Ischaemic preconditioning effect of prodromal angina pectoris is lost in patients with prior myocardial infarction.
145. An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial.
146. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology.
147. Effect of preinfarction angina pectoris on myocardial blush grade after reperfusion in first anterior wall acute myocardial infarction.
148. Effects of xuefu zhuyu decoction on functions of vascular endothelium in patients with unstable angina pectoris.
149. Are there socioeconomic differences in myocardial infarction event rates and fatality among patients with angina pectoris?
150. Decrease in plasma adiponectin concentrations in patients with variant angina pectoris.
151. Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris.
152. Associations between working conditions and angina pectoris symptoms among employed women.
153. An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial.
154. Treatment of chronic refractory angina pectoris--light at the end of the tunnel?
155. Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
156. Angina pectoris, dyspnea, fatigue, and edema after a non-ST-segment-elevation myocardial infarct.
157. Risk stratification of patients with angina pectoris by stress 99mTc-tetrofosmin myocardial perfusion imaging.
158. Therapy of stable angina pectoris: the uncomplicated patient.
159. Potential impact of myocardial perfusion scintigraphy as gatekeeper for invasive examination and treatment in patients with stable angina pectoris: observational study without post-test referral bias.
160. Images in cardiology: Left subclavian artery stenosis presenting as unstable angina pectoris after coronary artery bypass grafting.
161. Levels and values of inflammatory markers in patients with angina pectoris.
162. Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris.
163. Genotoxicity of thallium-201 in patients with angina pectoris undergoing myocardial perfusion study.
164. Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS).
165. Relationship of C-reactive protein to adverse cardiovascular events in patients treated by percutaneous coronary intervention for stable angina pectoris.
166. The incidence of stent-edge spasm after stent implantation in patients with or without vasospastic angina pectoris.
167. Advances in understanding the mechanisms of angina pectoris in cardiac syndrome X.
168. Anatomo-clinical correlation. Case 01/2005 -- Death in woman 59 years old with history of angina pectoris and cardiac failure with chest pain recurrence.
169. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris.
170. Physicians' attitudes to the pharmacological treatment of patients with stable angina pectoris.
171. Angina pectoris: a review of current and emerging therapies.
172. Epidural spinal cord stimulation in chronic refractory angina pectoris.
173. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris.
174. Different quantitative apoptotic traits in coronary atherosclerotic plaques from patients with stable angina pectoris and acute coronary syndromes.
175. The relationship between serum C-reactive protein levels and coronary artery disease in patients with stable angina pectoris and positive exercise stress test.
176. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study.
177. Decreased soluble cell adhesion molecules after tirofiban infusion in patients with unstable angina pectoris.
178. Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris.
179. Angina pectoris and normal coronary arteries: cardiac syndrome X.
180. Chronic therapeutically refractory angina pectoris.
181. Drug treatment of stable angina pectoris and mass dissemination of therapeutic guidelines: a randomized controlled trial.
182. Levels of serum IL-1beta, IL-2, IL-8 and tumor necrosis factor-alpha in patients with unstable angina pectoris.
183. Living with angina pectoris--a phenomenological study.
184. Refractory to medical treatment but not to nursing care: can we do more for patients with chronic angina pectoris?
185. Coexistence of familial hypertrophic cardiomyopathy and vasospastic angina pectoris in two brothers.
186. Relation of self-reported angina pectoris to inducible myocardial ischemia in patients with known coronary artery disease: the Heart and Soul Study.
187. Coronary vasomotor response is related to the angiographic extent of coronary sclerosis in patients with stable angina pectoris.
188. New-onset angina pectoris due to coronary artery aneurysms.
189. A rare cause of coronary obstruction and angina pectoris.
190. Angina pectoris without chest pain.
191. Reversible ischemic neurological deficit (RIND) due to exercise testing for the diagnosis of angina pectoris.
192. The current cost of angina pectoris to the National Health Service in the UK.
193. Enhanced external counterpulsation for refractory angina pectoris.
194. The effect of a neuropeptide Y Y1 receptor antagonist in patients with angina pectoris.
195. Bronchial asthma causing symptoms suggestive of angina pectoris.
196. Preoperative expectations and clinical outcome of transmyocardial laser treatment in patients with angina pectoris.
197. Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels.
198. Nicorandil-induced preconditioning as evidenced by troponin T measurements after coronary angioplasty in patients with stable angina pectoris.
199. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase.
200. Shoshin beriberi with vasospastic angina pectoris possible mechanism of mid-ventricular obstruction: possible mechanism of mid-ventricular obstruction.
201. Effects of moderate weight loss on anginal symptoms and indices of coagulation and fibrinolysis in overweight patients with angina pectoris.
202. Angina pectoris without chest pain: clinical implications of silent ischemia.
203. An autopsied case with a bicuspid aortic valve who had progressive angina pectoris and heart failure during follow-up of 27 years.
204. Reverse J-curve relation between diastolic blood pressure and severity of coronary artery lesion in hypertensive patients with angina pectoris.
205. Should troponin-T be assessed during exercise stress testing in patients with stable angina pectoris?
206. Preconditioning effect during coronary angioplasty in patients with stable angina pectoris.
207. The eighteenth-century origins of angina pectoris: predisposing causes, recognition and aftermath.
208. Prognostic implications of autonomic function assessed by analyses of catecholamines and heart rate variability in stable angina pectoris.
209. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris.
210. Severity of angina pectoris and risk of ischemic stroke.
211. Suspected angina pectoris: a rapid-access chest pain clinic.
212. Differential coronary calcification on electron-beam CT between syndrome X and coronary artery disease in patients with chronic stable angina pectoris.
213. Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study.
214. Dipyridamole in chronic stable angina pectoris; a randomized, double blind, placebo-controlled, parallel group study.
215. Treatment of stable angina pectoris: is there a role for dipyridamole?
216. Angina pectoris with special reference to its mechanical causes. 1938.
217. Angina pectoris in the heart transplant recipient: evidence of reinnervation.
218. Histopathologic evaluation of coronary artery thrombi obtained by directional coronary atherectomy in patients with restenosis-induced unstable angina pectoris.
219. Successfully treated unstable angina pectoris in a young Japanese female.
220. Platelet aggregability under shear is enhanced in patients with unstable angina pectoris who developed acute myocardial infarction.
221. Efficacy of anti-anginal drugs in the treatment of angina pectoris associated with silent myocardial ischemia: importance of quantitative Holter ECG data for patient activity.
222. Functioning and well-being of patients with type 2 diabetes or angina pectoris, compared with the general population.
223. Management of a patient with angina pectoris.
224. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris.
225. Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris.
226. QT interval dispersion: non-invasive marker of ischemic injury in patients with unstable angina pectoris?
227. Perioperative management of a patient requiring surgery for pituitary apoplexy and severe angina pectoris.
228. Dietary factor VII activation does not increase plasma concentrations of prothrombin fragment 1+2 in patients with stable angina pectoris and coronary atherosclerosis.
229. Circulating hepatocyte growth factor as a marker of thrombus formation in unstable angina pectoris.
230. Lipoprotein lipase activity is associated with severity of angina pectoris. REGRESS Study Group.
231. Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study.
232. Nitrate resistance in platelets from patients with stable angina pectoris.
233. In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris.
234. Abnormal myocardial blood flow distribution in patients with angina pectoris and normal coronary arteriograms.
235. Modulation of intrinsic cardiac neurons by spinal cord stimulation: implications for its therapeutic use in angina pectoris.
236. Endothelial nitric oxide synthase gene mutation and human leukocyte antigen analyzed in three cases of familial vasospastic angina pectoris.
237. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris.
238. Exercise testing, still the method of choice when evaluating patients with chronic stable angina pectoris.
239. Prognostic implications of results from exercise testing in patients with chronic stable angina pectoris treated with metoprolol or verapamil. A report from the Angina Prognosis Study In Stockholm (APSIS).
240. Sex differences in incidence rates and referral ratios for first attack angina pectoris.
241. Women with angina pectoris receive less antiplatelet treatment than men.
242. Cholesterol standardized plasma vitamin E levels are reduced in patients with severe angina pectoris.
243. Neurostimulation treatment for angina pectoris.
244. Negative stress echocardiographic responses in normotensive and hypertensive patients with angina pectoris, positive exercise stress testing, and normal coronary arteriograms.
245. Role of the vascular endothelium in patients with angina pectoris or acute myocardial infarction with normal coronary arteries.
246. Angina pectoris and oesophageal angina.
247. Intermediate-term clinical outcome following transmyocardial laser revascularization in patients with refractory angina pectoris.
248. Graphical comparison of coronary arterial culprit lesions in acute myocardial infarction and unstable angina pectoris.
249. D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction.
250. Morphologic correlation between atherosclerotic lesions of the carotid and coronary arteries in patients with angina pectoris.
251. Prognostic value of maximum ST-vector magnitude during the first 24 h of vectorcardiographic monitoring in patients with unstable angina pectoris.
252. Spinal cord stimulation for intractable angina pectoris.
253. Can patient satisfaction improve health among patients with angina pectoris?
254. Dynamic changes of QT dispersion as a predictor of myocardial ischemia on exercise testing in patients with angina pectoris.
255. Nitrate resistance in platelets from patients with stable angina pectoris.
256. Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction.
257. Spinal cord stimulation significantly decreases the need for acute hospital admission for chest pain in patients with refractory angina pectoris.
258. Clinical outcome of patients treated with spinal cord stimulation for therapeutically refractory angina pectoris. The Working Group on Neurocardiology.
259. Arterial remodelling of native human coronary arteries in patients with unstable angina pectoris: a prospective intravascular ultrasound study.
260. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN).
261. Coronary artery stenting in unstable angina pectoris: a comparison with stable angina pectoris.
262. Does coronary artery morphology predict favorable results of intracoronary thrombolysis in patients with unstable angina pectoris?
263. Follow-up care in general practice of patients with myocardial infarction or angina pectoris: initial results of the SHIP trial. Southampton Heart Integrated Care Project.
264. Heart rate variability and ischaemia in patients with coronary heart disease and stable angina pectoris; influence of drug therapy and prognostic value. TIBBS Investigators Group. Total Ischemic Burden Bisoprolol Study.
265. The patient developing chest pain at the onset of haemodialysis sessions--it is not always angina pectoris.
266. Safety of nifedipine in angina pectoris: a meta-analysis.
267. A case of variant angina pectoris with similar findings on both rest and matched exercise thallium-201 studies.
268. Nuclear factor-kappaB is selectively and markedly activated in humans with unstable angina pectoris.
269. Long-term follow-up after early intervention with intravenous diltiazem or intravenous nitroglycerin for unstable angina pectoris.
270. Surgical treatment of angina pectoris.
271. Angiographic progression in patients with angina pectoris and normal or near normal coronary angiograms who are restudied due to unstable symptoms.
272. Effects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris.
273. The successful use of spinal cord stimulation to alleviate intractable angina pectoris.
274. Low recurrence of angina pectoris after coronary artery bypass graft surgery with bilateral internal thoracic and right gastroepiploic arteries.
275. Tyrosine phosphorylation of platelet derived growth factor beta receptors in coronary artery lesions: implications for vascular remodelling after directional coronary atherectomy and unstable angina pectoris.
276. Prognosis of patients with angina pectoris or silent ischemia: exercise 99mTC-MIBI SPECT.
277. Assessment of exercise-induced silent myocardial ischemia by dipyridamole thallium imaging: (1). Its significance in stable angina pectoris.
278. Ischaemia during exercise and ambulatory monitoring in patients with stable angina pectoris and healthy controls. Gender differences and relationships to catecholamines.
279. Comparison of coronary hemodynamics during infusions of dobutamine and adenosine in patients with angina pectoris.
280. Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris: the ESBY study.
281. Regional myocardial blood flow redistribution as a cause of postprandial angina pectoris.
282. Is oxidative stress causally linked to unstable angina pectoris? A study in 100 CAD patients and matched controls.
283. Management of patients with angina pectoris by GPs: a study with standardized (simulated) patients in actual practice.
284. Angina pectoris and normal coronary angiograms.
285. Are there differences in late outcome after PTCA for angina pectoris after non-Q wave vs Q wave myocardial infarction?
286. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)
287. Combination treatment with trimetazidine and diltiazem in stable angina pectoris.
288. Addition of felodipine to metoprolol vs replacement of metoprolol by felodipine in patients with angina pectoris despite adequate beta-blockade. Results of the Felodipine ER and Metoprolol CR in Angina (FEMINA) Study. Working Group on Cardiovascular Research, The Netherlands (WCN).
289. New look to an old symptom: angina pectoris.
290. Anti-ischemic and anti-anginal effects of thoracic epidural anesthesia versus those of conventional medical therapy in the treatment of severe refractory unstable angina pectoris.
291. A case of effort angina pectoris with total obstruction of the left main coronary artery and extracardiac anastomose detected by angiography.
292. Psychosocial variables in female vs male patients with stable angina pectoris and matched healthy controls.
293. Angina pectoris and the personality factor: the relevance of psychosocial factors in myocardial ischaemia.
294. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm.
295. Effects of mental and physical stress on platelet function in patients with stable angina pectoris and healthy controls.
296. Serum cholesterol and long-term prognosis in middle-aged men with myocardial infarction and angina pectoris. A 16-year follow-up of the Primary Prevention Study in Göteborg, Sweden.
297. Angina pectoris after recovery from an acute coronary event--the role of psychological factors in Japanese vs North American patients.
298. Electron microscopic studies of phenotypic modulation of smooth muscle cells in coronary arteries of patients with unstable angina pectoris and postangioplasty restenosis.
299. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study.
300. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology.
301. Angina pectoris in patients with aortic stenosis and normal coronary arteries. Mechanisms and pathophysiological concepts.
302. Why angina pectoris in aortic stenosis.
303. Adenosine deaminase activity in blood of patients with stable angina pectoris.
304. Both endothelium-dependent and endothelium-independent function is impaired in patients with angina pectoris and normal coronary angiograms.
305. Antithrombotic treatment in stable coronary syndromes: long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris.
306. Angina pectoris and progressive fatigue in a 61-year-old man.
307. Angina pectoris in patients with a history of myocardial infarction.
308. Calcium antagonist drugs in hypertensive patients with angina pectoris.
309. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities.
310. Clinically stable angina pectoris is not necessarily associated with histologically stable atherosclerotic plaques.
311. Coronary stenosis progression differs in patients with stable angina pectoris with and without a previous history of unstable angina.
312. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group.
313. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris.
314. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
315. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms.
316. Value of intracoronary ultrasound and Doppler in the differentiation of angiographically normal coronary arteries: a prospective study in patients with angina pectoris.
317. Acute heavy alcohol intake increases silent myocardial ischaemia in patients with stable angina pectoris.
318. Abrupt cessation of short-term continuous treatment with isosorbide dinitrate may cause a rebound increase in silent myocardial ischaemia in patients with stable angina pectoris.
319. Thrombin activity and early outcome in unstable angina pectoris.
320. Characterization and identification of women with angina pectoris.
321. The effect of meals of differing composition on exercise tolerance in patients with angina pectoris.
322. Can improved quality of care reduce the costs of managing angina pectoris?
323. An 85-year-old case of Basedow's disease associated with high output heart failure and angina pectoris.
324. Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris.
325. Respiratory compromise: a rare complication of transcutaneous electrical nerve stimulation for angina pectoris.
326. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS)
327. Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris.
328. Rapid angiographic progression of coronary artery disease in patients with angina pectoris. The role of complex stenosis morphology.
329. Angina pectoris and disease progression.
330. A comparison of quality of life scores in patients with angina pectoris after angioplasty compared with after medical therapy. Outcomes of a randomized clinical trial. Veterans Affairs Study of Angioplasty Compared to Medical Therapy Investigators.
331. Coronary angioplasty in patients with stable angina pectoris and one-vessel disease.
332. Dose-response relationships of serum lipid measurements with the extent of coronary stenosis. Strong, independent, and comprehensive. ECAT Angina Pectoris Study Group.
333. Resting asynchronous left ventricular contraction abnormality analyzed by a phase method in spastic angina pectoris.
334. Differences in ischemic threshold and nitrate efficacy between normotensive and hypertensive patients with stable angina pectoris.
335. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris.
336. Vasospastic angina pectoris associated with apical hypertrophic cardiomyopathy.
337. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.
338. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group.
339. Incidence, clinical characteristics, and short-term prognosis of angina pectoris.
340. Losartan and angina pectoris.
341. Vasoconstrictor peptides and cold intolerance in patients with stable angina pectoris.
342. T lymphocyte activation in stable angina pectoris and after percutaneous transluminal coronary angioplasty.
343. Postcholecystectomy syndrome mimicking angina pectoris detected by the morphine provocation test.
344. Management of angina pectoris in general practice: a questionnaire survey of general practitioners.
345. Cardiology--I: Treatment of myocardial infarction, unstable angina, and angina pectoris.
346. Effects of ACE inhibitors on coronary haemodynamics and angina pectoris.
347. Effects of treatment with oral isosorbide dinitrate on platelet function in vivo; a double-blind placebo-controlled study in patients with stable angina pectoris.
348. Angina pectoris caused by pernicious anemia.
349. Accelerated thrombin generation during anticoagulation in patients with unstable angina pectoris.
350. Bronchial hyperresponsiveness to acetylcholine in patients with vasospastic angina pectoris.
351. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group.
352. Effects of spinal cord stimulation in angina pectoris induced by pacing and possible mechanisms of action.
353. Pronus angina (angina pectoris induced by stooping or crouching). A proposed mechanism.
354. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms.
355. Effect of beta-adrenoceptor blockade on atrial natriuretic peptide levels during exercise in angina pectoris.
356. Superoxide dismutase and catalase activity in patients with stable angina pectoris.
357. Rationale of exercise therapy in patients with angina pectoris with normal and impaired ventricular function.
358. Prophylactic nitrate therapy in angina pectoris--is there an optimal treatment regimen?
359. Increased plasma viscosity and erythrocyte aggregation: indicators of an unfavourable clinical outcome in patients with unstable angina pectoris.
360. Bopindolol in chronic stable angina pectoris: duration and extent of antianginal action.
361. Esophageal reflux and variant angina pectoris.
362. Transient increase of plasma lipoprotein(a) in patients with unstable angina pectoris. Does lipoprotein(a) alter fibrinolysis?
363. Abnormal coronary vasoconstriction as a predictor of restenosis after successful coronary angioplasty in patients with unstable angina pectoris.
364. Essential thrombocythemia associated with angina pectoris with unusual coronary artery findings.
365. John Fothergill and angina pectoris.
366. Distal coronary-artery constriction in angina pectoris.
367. Unstable angina pectoris and the progression to acute myocardial infarction. Role of platelets and platelet-derived mediators.
368. Early and long-term results of percutaneous transluminal coronary angioplasty for angina pectoris.
369. Pathophysiological findings, treatment and prognosis of angina pectoris.
370. Angiographic anatomy and pathogenic mechanisms of angina pectoris: implications regarding medical therapy.
371. Chronic administration of N-acetylcysteine fails to prevent nitrate tolerance in patients with stable angina pectoris.
372. Myocardial ischemia caused by distal coronary-artery constriction in stable angina pectoris.
373. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.
374. Development of tolerance to nifedipine in patients with stable angina pectoris.
375. Acute haemodynamic effects of cromakalim in patients with angina pectoris.
376. Pharmacokinetics of epanolol after acute and chronic oral dosing in elderly patients with stable angina pectoris.
377. Haemorrheological abnormalities in unstable angina pectoris: a relation independent of risk factor profile and angiographic severity.
378. Slow release nifedipine plus atenolol in chronic stable angina pectoris.
379. Influence of naloxone on the effects of high frequency transcutaneous electrical nerve stimulation in angina pectoris induced by atrial pacing.
380. Cold intolerance in patients with angina pectoris: effect of nifedipine and propranolol.
381. Antianginal effects of atenolol and pindolol in patients with stable effort angina pectoris.
382. Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response.
383. Xamoterol in mild to moderate heart failure: a subgroup analysis of patients with cardiomegaly but no concomitant angina pectoris. The European 'Corwin' Study Group.
384. Angina pectoris treated by ventricular plication.
385. Calcium channel blockers in black patients with angina pectoris.
386. The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.
387. Nifedipine and angina pectoris. Short-term changes in quantitative coronary angiography with nifedipine and clinical response to treatment in effort-induced, mixed, and spontaneous angina pectoris.
388. Percutaneous transluminal coronary angioplasty of one vessel for refractory unstable angina pectoris: efficacy in single and multivessel disease.
389. Laser recanalisation of coronary arteries by metal-capped optical fibres: early clinical experience in patients with stable angina pectoris.
390. Contraindications for percutaneous transluminal coronary angioplasty in treatment of unstable angina pectoris.
391. On the pathogenesis of angina pectoris and its silence.
392. Epidural spinal electrical stimulation in severe angina pectoris.
393. Treatment of angina pectoris with nifedipine: a double blind comparison of nifedipine and slow-release nifedipine alone and in combination with atenolol.
394. The medical treatment of angina pectoris.
395. Angina pectoris and bilateral diffuse infiltrates. Lymphoplasmacytoid lymphoma.
396. Left ventricular function and oesophageal function in patients with angina pectoris and normal coronary angiograms.
397. Myocardial infarction and angina pectoris in young women.
398. Observations on the warm up phenomenon in angina pectoris.
399. Exertional gastro-oesophageal reflux: a mechanism for symptoms in patients with angina pectoris and normal coronary angiograms.
400. Left ventricular global and regional function during lumbar epidural anesthesia in patients with and without angina pectoris. Influence of volume loading.
401. A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris.
402. Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris.
403. Unpredictable cause of early recurrence of angina pectoris after successful double coronary angioplasty.
404. Effect of the specific thromboxane receptor blocking drug AH23848 in patients with angina pectoris.
405. Angina pectoris-like pain provoked by intravenous infusion of adenosine.
406. Optimum pacing mode for patients with angina pectoris.
407. Angina pectoris-like pains provoked by intravenous adenosine.
408. Left ventricular dysfunction in patients with angina pectoris and normal coronary angiograms.
409. Angina pectoris-like pain provoked by intravenous infusion of adenosine.
410. Physicians' attitudes to four common problems: hypertension, atrial fibrillation, transient ischaemic attacks, and angina pectoris.
411. Course of angina pectoris after an acute coronary event.
412. Thallium 201 perfusion imaging after the treatment of unstable angina pectoris--relationship to clinical outcome.
413. Angina pectoris-like pains provoked by intravenous adenosine.
414. Angina pectoris-like pain provoked by intravenous adenosine in healthy volunteers.
415. Acceptance of transcutaneous nitroglycerin patches by patients with angina pectoris.
416. Treatment of angina pectoris with nifedipine and atenolol: efficacy and effect on cardiac function.
417. Randomized double-blind placebo-controlled comparison of nicardipine and nifedipine in patients with chronic stable angina pectoris.
418. Improvement in angina pectoris with alpha adrenoceptor blockade.
419. Verapamil in angina pectoris.
420. Failure to appreciate implications of effects of cold in exertional angina pectoris.
421. Comparison of oxyfedrine and atenolol in angina pectoris--a double-blind study.
422. How important is a history of chest pain in determining the degree of ischaemia in patients with angina pectoris?
423. Efficacy of transdermal glyceryl trinitrate in the treatment of chronic stable angina pectoris.
424. Improvement in angina pectoris with alpha adrenoceptor blockade.
425. Nickel concentrations in serum of patients with acute myocardial infarction or unstable angina pectoris.
426. Assessment of dermal glyceryl trinitrate and isosorbide dinitrate for patients with angina pectoris.
427. Is there an indication for coronary angiography in patients under 60 years of age with no or minimal angina pectoris after a first myocardial infarction?
428. Nicardipine for stable angina pectoris.
429. Oral labetalol in the management of stable angina pectoris in normotensive patients.
430. Effects of combined alpha and beta adrenoceptor blockade in patients with angina pectoris. A double blind study comparing labetalol with placebo.
431. Beneficial effects of diltiazem and propranolol, alone and in combination, in patients with stable angina pectoris.
432. Effects of nicardipine on coronary blood flow, left ventricular inotropic state and myocardial metabolism in patients with angina pectoris.
433. Effect of partial agonist activity in beta blockers in severe angina pectoris: a double blind comparison of pindolol and atenolol.
434. The reproducibility of hemodynamic, electrocardiographic, and gas exchange data during treadmill exercise in patients with stable angina pectoris.
435. Primary cardiac amyloidosis in a young man presenting with angina pectoris.
436. Computer aided exercise electrocardiographic testing and coronary arteriography in patients with angina pectoris and with myocardial infarction.
437. Nadolol compared to propranolol for treating chronic stable angina pectoris.
438. The effects on left ventricular performance of nifedipine and verapamil in exercise-induced angina pectoris.
439. The clinical and hemodynamic effects of propranolol, pindolol and verapamil in the treatment of exertional angina pectoris.
440. Comparative effects of long-acting and conventional propranolol on stress-induced angina pectoris and on frequency of ventricular premature beats.
441. Regional left ventricular contraction abnormality during early systole in patients with angina pectoris. Assessment with radionuclide ventriculography.
442. The acute effects of nifedipine on red cell deformability in angina pectoris.
443. Denial predicts favorable outcome in unstable angina pectoris.
444. Verapamil administered twice daily in stable angina pectoris.
445. A case report of successful coronary revascularization in a patient with severe angina pectoris and hypothyroidism.
446. Fatal cardiac arrest during cardiac catheterization for angina pectoris. A marker of quadruple vessel disease.
447. Increased coronary sinus lactate concentration during pacing induced angina pectoris after clinical improvement by glyceryl trinitrate.
448. Haemodynamic dose-response effects of i.v. penbutolol in angina pectoris.
449. Articles to Read in Other Journals: Long-term Results of Prospective Randomised Study of Coronary Artery Bypass Surgery in Stable Angina Pectoris.
450. Simultaneous recording of continuous arterial pressure, heart rate, and ST segment in ambulant patients with stable angina pectoris.
451. Treatment of angina pectoris with nifedipine.
452. Prolonged plasma half-life after oral isosorbide dinitrate in patients with angina pectoris.
453. Treatment of angina pectoris with nifedipine: importance of dose titration.
454. Correlates of angina pectoris among men awaiting coronary by-pass surgery.
455. Thoracic outlet syndrome mimicking angina pectoris with elevated creatine phosphokinase values.
456. Efficacy of sustained-release buccal nitroglycerin in patients with angina pectoris. New and long-acting therapy demonstrated by exercise.
457. The effect of cold on patients with angina pectoris--a review.
458. The effect of glyceryl trinitrate ointment on heart rate--corrected systolic time intervals in angina pectoris.
459. The symptomatic and objective effects of nifedipine in combination with beta-blocker therapy in severe angina pectoris.
460. Diurnal variation in exercise responses in angina pectoris.
461. Angina pectoris at rest.
462. Alternatives to beta-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol.
463. Adverse response to nifedipine in unstable angina pectoris.
464. Are propranolol and nifedipine synergistic in angina pectoris?
465. Comparison of antianginal efficacy of one conventional and three long acting beta-adrenoreceptor blocking agents in stable angina pectoris.
466. Comparison of nadolol, a new long-acting beta-receptor blocking agent, and placebo in the treatment of stable angina pectoris.
467. Effects of nitrates on R-wave variations after exercise in coronary heart disease: differences in patients with and without angina pectoris.
468. The combination of nifedipine and propranolol in the management of patients with angina pectoris.
469. The prolonged effect of pentaerythritol tetranitrate on exercise capacity in stable effort angina pectoris.
470. Effect of oral propranolol on rest and exercise left ventricular ejection fraction, volumes, and segmental wall motion in patients with angina pectoris. Assessment with equilibrium gated blood pool imaging.
471. T wave changes and postinfarction angina pectoris predictive of recurrent myocardial infarction.
472. Effect of a calcium inhibitor, nifedipine, on exercise tolerance in patients with angina pectoris: a double-blind study.
473. Oxyfederine and propranolol--a controlled trial in angina pectoris.
474. The effect of prenylamine on the QT interval of the resting electrocardiogram in patients with angina pectoris.
475. Effect of nifedipine on exercise tolerance in angina pectoris.
476. Efficacy of nifedipine in the treatment of angina pectoris and chronic airways obstruction.
477. A controlled comparison of oxyfedrine, isosorbide dinitrate and placebo in the treatment of patients suffering attacks of angina pectoris.
478. Interaction between cigarettes and propranolol in treatment of angina pectoris.
479. Haemodynamic and electrocardiographic effects of frusemide during supine exercise in patients with angina pectoris.
480. Evidence for emotionally-induced coronary arterial spasm in patients with angina pectoris.
481. Haemodynamic and metabolic effects of atenolol in patients with angina pectoris.
482. Angina pectoris during inhalation of cold air. Reactions to exercise.
483. Pathogenetic mechanisms of angina pectoris: expanding views.
484. Dietary fat-induced postprandial lipemia: effect on arterial oxygen saturation and plasma lactate, triglyceride, and cholesterol levels in subjects with angina pectoris.
485. Unstable angina pectoris. Factors influencing operative risk.
486. ECG predictors of coronary anatomy and left ventricular function. Findings in patients with typical angina pectoris.
487. High dose propranolol in the treatment of angina pectoris: relationship of dose to blood levels and hemodynamic consequences.
488. Propranolol versus coronary bypass for angina pectoris.
489. Praecordial surface mapping after exercise in evaluation of propranolol for angina pectoris.
490. Dressler's syndrome and angina pectoris relieved by surgery.
491. Selected items from the history of pathology. Angina pectoris.
492. Glyceryl trinitrate ointment in angina pectoris.
493. Angina pectoris with normal coronary arteries in Shy-Drager syndrome.
494. Routine exercise testing in angina pectoris.
495. Diagnostic value of routine exercise testing in hospital patients with angina pectoris.
496. Long-acting nitrates in the prophylaxis of angina pectoris.
497. Roentgenogram of the month: angina pectoris associated with a metallic fragment in the heart.
498. Refractory angina pectoris.
499. Blood volume in angina pectoris.
500. Treatment of variant angina pectoris with perhexilene maleate.
501. Myocardial ischaemia in patients with frequent angina pectoris.
502. Open evaluation of labetalol in the treatment of angina pectoris occurring in hypertensive patients.
503. Relationship between hypertension and angina pectoris.
504. Myocardial ischaemia in patients with frequent angina pectoris.
505. Comparative effect of nadolol and propranolol on exercise tolerance in patients with angina pectoris.
506. Influence of glyceryl trinitrate during supine and upright exercise in patients with angina pectoris.
507. Effect of prolonged intensive training on cardiorespiratory response in patients with angina pectoris.
508. Comparative trial of perhexiline maleate and oxprenolol in patients with angina pectoris.
509. Comparison of atenolol with propranolol in the treatment of angina pectoris with special reference to once daily administration of atenolol.
510. Abnormal left ventricular wall movement during early systole in patients with angina pectoris.
511. Sexual intercourse and angina pectoris.
512. The effect of lidoflazine on exercise tolerance in patients with angina pectoris.
513. Coronary surgery for unstable angina pectoris. Incidence and mortality of perioperative myocardial infarction.
514. Variant angina pectoris. The controversies continue.
515. Variant angina pectoris. Clinical presentations, coronary angiographic patterns, and the results of medical and surgical management in 42 consecutive patients.
516. Drug treatment of chronic stable angina pectoris.
517. Esophageal pain misdiagnosed as angina pectoris.
518. Drug treatment of chronic stable angina pectoris.
519. Thyrotoxicosis and lactate-producing angina pectoris with normal coronary arteries.
520. Coronary artery disease and its risk factors in families of young men with angina pectoris and in controls.
521. Management of stable angina pectoris.
522. Double-blind comparison of verapamil and practolol in the treatment of angina pectoris.
523. TRANSIENT ISCHEMIC EVENTS OF THE HEART (ANGINA PECTORIS).
524. Medical versus surgical treatment of stable angina pectoris: progress report of a large scale study.
525. Oxprenolol in angina pectoris proceedings.
526. Angina pectoris in mitral stenosis--observations on a mechanism.
527. Antilipolytic therapy in angina pectoris. Reduction of exercise-induced ST segment depression.
528. Significance of angina pectoris in aortic valve stenosis.
529. An eighteen months' study of the clinical response to metoprolol, a selective beta1-receptor blocking agent, in patients with angina pectoris.
530. Letter: Perhexiline maleate in angina pectoris.
531. Letter: Prognosis of new and worsening angina pectoris.
532. Prognosis of new and worsening angina pectoris.
533. Painless ST-segment depression in patients with angina pectoris. Correlation with daily activities and cigarette smoking.
534. Unstable angina pectoris. Clinical, angiographic, and myocardial scintigraphic observations.
535. Effects of the cardioselective beta-adrenergic receptor blocking agent metoprolol in angina pectoris. Subacute study with exercise tests.
536. Constancy of pressure-rate product in pacing-induced angina pectoris.
537. Rate-dependent left bundle branch block with angina pectoris and normal coronary arteriograms.
538. Editorial: Discontinuation of propranolol therapy. Cause of rebound angina pectoris and acute coronary events.
539. Angina pectoris, ECG findings and blood pressure of foundry workers in relation to carbon monoxide exposure.
540. Treatment of spontaneous angina pectoris with beta blocking agents. A clinical, electrocardiographic, and haemodynamic appraisal.
541. Reassessment of failed beta-blocker treatment in angina pectoris by peak-exercise heart rate measurements.
542. Variant angina pectoris. Four cases to illustrate the spectrum.
543. Unusual hemodynamic response during exercise-induced angina pectoris.
544. Localization of left ventricular ischaemia in angina pectoris by cineangiography during exercise.
545. Maximal exercise testing in patients with spontaneous angina pectoris associated with transiet ST segment elevation. Risks and electrocardiographic findings.
546. Letter: Tolamolol in treatment of angina pectoris.
547. Letter: tolamolol in treatment of angina pectoris.
548. Letter: Tolamolol in treatment of angina pectoris.
549. Variant angina pectoris due to coronary artery spasm.
550. Effectiveness of isosorbide dinitrate and nitroglycerin in relieving angina pectoris during uninterrupted exercise.
551. The surgical treatment of unstable angina pectoris.
552. Left and right heart haemodynamics during spontaneous angina pectoris. Comparison between angina with ST segment depression and angina with ST segment elevation.
553. Effect of aorto-coronary grafts and native vessel patency on the occurrence of angina pectoris after coronary bypass surgery.
554. Double-blind comparison of tolamolol, propranolol, practolol, and placebo in the treatment of angina pectoris.
555. Clinical, haemodynamic, and coronary angiographic correlates of angina pectoris in patients with severe aortic valve disease.
556. Further variant patterns within Prinzmetal angina pectoris.
557. An evaluation of sotalol, a beta-blocking agent, in patients with angina pectoris.
558. Effect of a new beta-adrenergic blocking agent, ICI 66o82, on exercise haemodynamics and airway resistance in angina pectoris.
559. Central haemodynamics during oxygen breathing in angina pectoris.
560. Central haemodynamics during spontaneous angina pectoris.
561. Diphenylhydantoin in angina pectoris.
562. A double-blind trial of vitamin E in angina pectoris.
563. Double-blind crossover study of diphenylhydantoin in angina pectoris.
564. Late results of aortocoronary bypass grafts in 100 patients with stable angina pectoris.
565. Investigation of the physiological basis for increased exercise threshold for angina pectoris after physical conditioning.
566. Cardiovascular effects of weight reduction in obese patients with angina pectoris.
567. Angina pectoris with syncope due to paroxysmal atrioventricular block: role of ischaemia. Report of two cases.
568. Clinical diagnosis of stable angina pectoris.
569. Vitamin E in angina pectoris.
570. Carotid sinus nerve stimulation in the management of intractable angina pectoris: four-year follow-up.
571. Coronary artery spasm associated with variant angina pectoris.
572. Late systolic bulging of left ventricle in patients with angina pectoris. A form of asynchronous contraction.
573. THE USE OF NON-INVASIVE TECHNIQUES IN MANAGEMENT OF PATIENTS WITH ANGINA PECTORIS ON ORAL PROPRANOLOL.
574. PRINZMETAL'S VARIANT ANGINA PECTORIS WITH NORMAL CORONARY ARTERIOGRAMS: EFFECT OF LONG-TERM RESERPINE TREATMENT.
575. The "natural" history of severe angina pectoris with intensive medical therapy alone: a five year prospective study of 133 patients.
576. Editorial: Digitalis and angina pectoris.
577. Nonocclusive coronary disease associated with Prinzmetal's angina pectoris.
578. Repetitive transient myocardial ischemia, Prinzmetal type, without angina pectoris, presenting with Stokes-Adams attacks.
579. Drugs for angina pectoris.
580. Drugs for angina pectoris.
581. Intractable angina pectoris in the 65 to 79 year age group: a surgical approach.
582. Ventricular fibrillation in the course of Prinzmetal's angina pectoris. Report of two cases.
583. Highway travel and angina pectoris.
584. Results of conservative treatment of angina pectoris in candidates for aortocoronary saphenous vein bypass.
585. Effects of a new cardioselective beta-adrenergic blocker (tolamolol) on exercise tolerance in patients with angina pectoris.
586. The use of indirect indices of myocardial oxygen consumption in evaluating angina pectoris.
587. Comparison of two adrenergic beta-receptor blocking agents, alprenolol and propranolol, in treatment of angina pectoris.
588. The effect of AH 5158, pindolol, propranolol, D-propranolol on acute exercise tolerance in angina pectoris.
589. Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris.
590. Comparison of adrenergic beta-receptor antagonists in angina pectoris.
591. Left ventricular haemodynamics before and soon after saphenous vein bypass graft operation for angina pectoris.
592. Clinical evaluation of oxprenolol in angina pectoris.
593. Clinical, electrocardiographic, and haemodynamic effects of digitalis (ouabain) in angina pectoris.
594. Angina pectoris: an approach to management.
595. Clinical evaluation of perhexiline maleate in patients with angina pectoris.
596. Clinical, electrocardiographic, and haemodynamic effects of long-term use of propranolol in Prinzmetal's variant angina pectoris.
597. Comparison of the symptomatic, electrocardiographic and haemodynamic effects of acute and long term -blockade in angina pectoris.
598. Comparison of adrenergic beta-blocking drugs in angina pectoris.
599. Assessment of propranolol in angina pectoris. Clinical dose response curve and effect on electrocardiogram at rest and on exercise.
600. Double-blind three-dose trial of oral alprenolol in angina pectoris.